GKB Ophthalmics enterprise value

Share price at each year-end
Tap a line for its trendCurrentlast closeFY23Mar 2023
30.1—
0.10.1
11.211.2
41.2—
11.111.1
₹81.80—
38.738.7
29.0%29.0%
0.27×—
1.49×—
−37.61×—
−11.34×—
−35.99×—
Reference items — trailing FY values
27.727.7
−1.1−1.1
−3.6−3.6
−1.1−1.1
−2.0−2.0
−2.0−2.0
0.80.8
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

GKB₹59.68

GKB Ophthalmics Limited

· Pharma & Health
₹ CrorePeersFABTECHLAXMIDENTLTARSONSFISCHERMcap ₹30.1 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
Current
last close
Market Capitalization—30.1
- Cash, Equiv & ST Investments0.10.1
+ Total Debt11.211.2
Enterprise Value—41.2
Net Debt (memo)11.111.1
EV per Share—81.80
Total Capital38.738.7
Total Debt/Total Capital28.9628.96
Total Debt/EV—0.27
EV/Sales—1.49
EV/EBITDA—-37.61
EV/EBIT—-11.34
EV/Operating Cash Flow—-35.99
Reference Items — Trailing FY Values
Sales27.727.7
EBITDA-1.1-1.1
EBIT-3.6-3.6
Operating Cash Flow-1.1-1.1
Free Cash Flow-2.0-2.0
FCFF (free cash flow to the firm)-2.0-2.0
Capital Expenditure0.80.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY23 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.